Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

World Cup Campaign To Build Centers To Provide HIV/AIDS Education, Other Services To At-Risk African Youth
Authorities in South Africa have begun construction of one of the 20 planned Football for Hope centers in Africa -- part of a 2010 World Cup campaign called "20 Centers for 2010" aimed at reducing the prevalence of HIV/AIDS, poverty and crime in local communities -- the AP/Google.com reports. The center under construction in South Africa"s Khayelitsha township will include a soccer field, community center and after-school programs that will focus on sex education and HIV/AIDS education. The International Federation of Football Association, or FIFA, in alliance with Streetfootballworld, a network of development groups, is providing the campaign with $10 million in funding. Ghana, Kenya, Mali, Namibia, Rwanda and other African countries will be home to the remaining 19 centers.According to FIFA President Joseph Blatter, the campaign "emphasizes the power of football far beyond the boundaries of the pitch." He added that the centers will "provide a platform for communities to address social issues such as children"s rights, education, health, HIV/AIDS prevention and will leave a legacy for Africa that will last long after the final whistle of the 2010 FIFA World Cup has been blown." Helen Zille, premier of the Western Cape Province, said construction of the center in the township "shows what we can do when we focus on getting things right rather than concentrating on what"s wrong," adding that she hopes the center is successful with its HIV/AIDS education efforts. The center will be run by Grassroots Soccer, an HIV/AIDS education organization that uses the sport to educate youth. Nocawe Tyali, a life-skills and football teacher who works with teenagers, said the new center will give young people an alternative to high-risk behaviors and enable the area to offer more youth football programs that include an HIV/AIDS prevention message (Nullis, AP/Google.com, 5/25).

InfoMedics Presents Studies Highlighting Adults' Experiences With ADHD Drug
InfoMedics, Inc., the patient feedback company, recently co-authored two posters detailing patients" experiences with the attention-deficit/hyperactivity disorder (ADHD) drug lisdexamfetamine dimesylate (LDX).
News of the day
New Broad-Spectrum Vaccine To Prevent Cervical Cancer Induces Strong Responses In Animals
Mice and rabbits immunized with a multimeric-L2 protein vaccine had robust antibody responses and were protected from infection when exposed to human papillomavirus (HPV) type 16 four months after vaccination, according to a new study published in the May 26 online issue of the Journal of the National Cancer Institute.
Oncology

Strativa's New Drug Application For Ondansetron Orally Dissolving Film Strip Accepted By FDA

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for ondansetron orally dissolving film strip (ODFS). Strativa is seeking approval of ondansetron ODFS for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and surgery. The ODFS, a new oral formulation of ondansetron designed to rapidly dissolve on the tongue, was developed using MonoSol Rx" proprietary PharmaFilm(TM) thin film technology. In clinical studies, this formulation demonstrated bioequivalence to ondansetron orally disintegrating tablets (ODT), both with and without water. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, Strativa expects the FDA will complete its review or otherwise respond to the NDA by the first quarter of 2010. "We are very pleased with the acceptance of our NDA submission and look forward to cooperating with the FDA on its review," said John A. MacPhee, President, Strativa Pharmaceuticals. "We believe the quick dissolving film strip formulation of ondansetron offers a convenient and easy-to-administer option for managing nausea and vomiting associated with chemotherapy, radiotherapy and surgery." Nausea and vomiting is a common side effect associated with chemotherapy, radiation and surgery. Left untreated, nausea and vomiting can have serious consequences such as exhaustion, dehydration and undernourishment, which can interfere with treatment and healing. In June 2008, Strativa and MonoSol Rx entered into an exclusive licensing agreement under which Strativa acquired the U.S. commercialization rights to ondansetron orally dissolving film strip. About Strativa Pharmaceuticals Strativa Pharmaceuticals is the proprietary products division of Par Pharmaceutical, Inc. Strativa is committed to developing and marketing novel prescription drugs. Its initial focus is on supportive care therapeutics in HIV and oncology. Drawing on the specialty products expertise of its staff, Strativa possesses the res to prepare products for commercialization and to help ensure their success after launch. About Par Pharmaceutical Par Pharmaceutical, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. Safe Harbor Statement Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company"s Annual Report on Form 10-K for the year ended December 31, 2008, in other of the Company"s filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements. Par Pharmaceutical Companies, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009